Videos from Masterclass Now Available
You can now access the videos through the Learning Materials section of this course.
Claim your Certificate and Credit
To claim your certificate, you must first complete the Post Examination and the Evaluation. To do this, click the “Get Started” or “Login” button. Please note, the button you see is dependent on whether you are currently logged in. Upon clicking this button, follow the cues to move through the evaluation to receive your certificate.
Overview
Masterclass in Cardiac Amyloidosis features in-depth sessions led by expert cardiologists, multimodality imagers, hematologists, and neurologists to discuss the disease spectrum, diagnosis, and management of cardiac amyloidosis. The course will focus on:
- the pathogenesis of cardiac amyloidosis;
- diagnostic techniques and pitfalls;
- management strategies;
- mechanisms to facilitate early diagnosis; and
- treatment and management.
Statement of Need
The sessions will provide an in-depth discussion of cardiac amyloidosis and its pathogenesis, diagnostic techniques and pitfalls, management strategies, mechanisms to facilitate early diagnosis, treatment and management, and challenging case studies presented by leading internationally recognized experts in transthyretin cardiac amyloidosis. Masterclass sessions will include clinically relevant cases where appropriate.
Target Audience
The program is intended for the multidisciplinary care team involved with cardiac amyloidosis patients; primary care, general cardiologists, heart failure specialists, nuclear cardiologists, multimodality imaging cardiologists, hematologists, neurologists, nurse practitioners, physicians' assistants and nurses.
Learning Objectives
After participating in this activity, learners should be able to achieve the following:
• Describe amyloidosis, including specific types, cardiac features, and disease burden
• Identify barriers to identification and diagnosis of patients suspected of ATTR
• Summarize the diagnostic evaluation for CA including multimodality imaging and laboratory testing and identify prognostic markers
• Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR)
• Explain the importance of genetic testing in hATTR
• Discuss the therapeutic landscape and impact on disease burden
• Define appropriate treatment and management strategies for patients with heart failure
• Formulate strategies for development of a multidisciplinary care team
• Evaluate potential community outreach activities to identify at-risk patients
Overall Goal
The overall goal is to improve the knowledge, competence, and performance of healthcare providers (HCPs) involved in patient care and who see patients at risk for cardiac amyloidosis by enhancing their skills for diagnosing, treating and managing patients with amyloidosis, with a focus on transthyretin cardiomyopathy (ATTR-CM).
Accreditation and Continuing Education Credit
The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Evaluation Deadline: AMA PRA Category 1 Credits™ and Participation Credits = December 31, 2025. The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Nuclear Cardiology designates this internet live activity for a maximum of 10 AMA PRA Category 1 Credits™.
Participants can earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. To receive 10 MOC points for participating in this activity, you must be a diplomate of the American Board of Internal Medicine (ABIM) and you must have an ABIM account. If you have not yet established an online account, you will need to visit the ABIM at www.abim.org, or contact ABIM via phone by calling: 1-800-441-ABIM or 215-446-3590. Mon - Fri 8:30 a.m. - 8:00 p.m. ET, Sat 9:00 a.m. - 12:00 p.m. ET.
Disclosure Policy and Disclosures
As an accredited provider of the Accreditation Council for Continuing Medical Education (ACCME), The American Society of Nuclear Cardiology (ASNC) adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. In compliance with these standards, it is ASNC’s policy to ensure balance, independence, objectivity, and scientific merit in all of its educational activities through the disclosure of relevant financial relationship with ineligible companies and mitigation of conflicts of interest. The financial interest or relationships requiring disclosure are outlined in ASNC’s CME Conflict of Interest Policy. All planners, reviewers, and presenters involved with this activity were required to disclose all financial relationships.
The American Society of Nuclear Cardiology has reviewed this activity’s faculty disclosures and mitigated or managed all identified conflicts of interest.
The following planners, presenters, peer reviewers, and staff reported no financial relationships:
Tawfiq Al-lahham, MD
Renee Bullock-Palmer, MD
Foluso Fakorede, MD
Matthew Parker, MD
Andrew Staron, MD
Linda Giering, PhD (ASNC staff)
Wendy Passerell (ASNC staff)
The following planners, presenters, peer reviewers, staff reported financial relationships:
Kevin Alexander: Consultant – Arbor Biotechnologies, Attralus, Prothena, Intellia, Alexion, Pfizer, Alnylam, Novo Nordisk; Advisory Board - Arbor Biotechnologies
Panithaya Chareonthaitawee: Consultant – GE Healthcare; Royalty - UpToDate
Sarah Cuddy: Speaker/Advisory Board – Novo Nordisk, Pfizer, Astra Zeneca, Alexion, BridgeBio; Advisory Board – Intellia; Consultant – Life Molecular Imaging; Medical Monitor – Attalus
Anita D’Souza: Clinical trial support – Abbvie, Alexion, Janssen, Prothena, Novartis, Regeneron; Consultant – Abbvie, Bristol Myers Squibb, Prothena; Advisory Board – Abbvie, Bristol Myers Squibb, Janssen, Pfizer; Steering Committee – Abbvie, Janssen, Prothena; Independent Review Committee – Janssen; Data Monitoring Committee - Bristol Myers Squibb
Angela Dispenzieri: Advisory board – Janssen, HaemalogiX; Research grants – Alnylam, Pfizer, BMS, Takeda; Data monitoring safety committee – Oncopeptides, Sorrento; Independent review committee - Janssen
Mazen Hanna: Advisory Board – Pfizer, Alnylam, Eidos, Ionis, Alexion, Novo Nordisk, Attralus
Isabelle Lousada: Speaker/Advisory Board – Alexion
Saurabh Malhotra: Speaker’s bureau – Pfizer, Alnylam; AstraZeneca; Consultant – Viz.ai; Advisory Board – Pfizer, Alnylam
Ahmad Masri: Research grants – Pfizer, Ionis, Attralus, Janssen, Cytokinetics; Consultant/Advisory Board – BMS, Cytokinetics, Eidos/BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Prothena, BioMarin, AstraZeneca, Tenava
Mathew Maurer: Advisory Board/Grant support – Pfizer, BridgeBio, Alnylam, Ionis, Intellia; Advisory Board – Novo Nordisk
Frederick Ruberg: Research grants – Pfizer, Alnylam, Akcea, Anumana, TriNetX; Consultant/Advisory Board – AstraZeneca, Attralus
Prem Soman: Research grant – Pfizer; Consultant – Alnylam, Spectrum Dynamics, Eidos, Pfizer
Jonathan Wall: Stock/Consultant/Research support - Attralus
Ashutosh Wechalekar: Honorarium/Advisory Board – Janssen, Attralus, Pfizer, Prothena, GSK
Continuing Education Term of Approval
Release Date: March 9, 2025
Expiration Date: December 31, 2025
(A fee will be charged for claiming credit after the expiration date)
Method of Participation
The Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management took place March 7-9, 2025 as an Internet Live activity. Attendees may use the OnDemand course to access post-test, faculty evaluation and certificate.
Acknowledgement of Commercial Support
This activity is supported by an unrestricted educational grant from BridgeBio.